Tumoricidal and Radiosensitizing Effects of Onconase; Studies in Human Prostate Carcinoma, Lung Adenocarcinoma and Rat Hepatoma
Business Wire - October 7, 1999
BLOOMFIELD, N.J.--(BUSINESS WIRE)--Oct. 7, 1999--
Alfacell Corporation (OTC BB:ACEL). Independent in vivo studies showed that ONCONASE(R) was significantly more effective than the control treatment in inhibiting tumor growth in transplanted human and murine tumor models... (Read More)
Inhibition Of Mesothelioma Cell Growth By Pleural Sclerosing Agents: Comparison Of Doxycycline, Bleomycin, And Talc
Chest - October 1, 1999, by Jeffrey B Rubins
Purpose: Malignant mesothelioma (MM) causes profound morbidity and nearly universal mortality that is refractory to conventional treatment modalities of aggressive surgery, radiotherapy or chemotherapy. Pleural sclerosis with tale, Neomycin, and doxycycline has been used ... (Read More)
Advances in the Treatment of Malignant Pleural Mesothelioma - )
Chest - August 1, 1999, by Daniel H. Sterman,
Larry R. Kaiser,
Steven M. Albelda
Malignant pleural mesothelioma is a neoplasm that is commonly fatal and for which there are no widely accepted curative approaches. Mesothelioma is unresponsive to most chemotherapy and radiotherapy regimens, and it typically recurs even after the most aggressive attempts... (Read More)
Soft Tissue Sarcomas: Integrating Primary Care Recognition with Tertiary Care Center Treatment
American Family Physician - August 1, 1999, by Thomas C. Rosenthal,
William Kraybill
Soft tissue sarcomas account for fewer than 1 percent of malignancies diagnosed annually in the United States. These tumors usually present as an asymptomatic mass. Any lesion larger than 5 cm in diameter should be considered suspicious. Radiographs should be obtained as ... (Read More)
SmallCaps Online LLC Announces Investment Opinion on Aronex Pharmaceuticals, Inc
Business Wire - July 29, 1999
NEW YORK--(BUSINESS WIRE)--July 29, 1999--
SmallCaps Online LLC Initiates Coverage of Aronex Pharmaceuticals,
Inc. With a BUY Recommendation
Visit SmallCaps Online's Web Site at www.SmallCapsOnline.com for
Detailed Report
SmallCaps Online LLC announced today tha... (Read More)
Finger Clubbing and a Lung Mass - )
Chest - June 1, 1999, by John D. Urschel,
Timothy M. Anderson,
Brian P. Whooley
(CHEST 1999; 115:1735-1737)
A 71-year old man complained of enlargement of A his distal phalanges. He did not have any other musculoskeletal complaints, and he denied pulmonary symptoms. He was a heavy smoker. Medical history was unremarkable. He did not have symptoms o... (Read More)
Leukocyte Infiltration and Secretion of Cytokines in Pleural Drainage Fluid After Thoracic Surgery
Chest - June 1, 1999, by Dietmar Weissflog,
Claus Kroegel,
Werner Luttmann,
Paul Reinhard Grahmann,
Joachim Hasse
Impaired Cytokine Response in Malignancy and Postoperative Complications
Study objective: To assess the postoperative course of pleural leukocyte counts and cytokine concentrations in patients with malignant and nonmalignant lung disease who underwent thoracic surgery.
... (Read More)
ALFACELL Presents Promising Breast Cancer Data At AACR Conference; Combination of ONCONASE and Doxorubicin Shows Survival Benefit in Mice
Business Wire - April 13, 1999
BLOOMFIELD, N.J.--(BUSINESS WIRE)--April 13, 1999--
ALFACELL Corporation (NASDAQ: ACEL) presented the results of in vivo studies conducted by the National Cancer Institute at the 90th Annual Meeting of the American Association for Cancer Research in Philadelphia, PA.
... (Read More)
Multicentre randomised controlled trial of nursing intervention for breathlessness in patients with lung cancer
British Medical Journal - April 3, 1999, by Mary Bredin,
Jessica Corner,
Meinir Krishnasamy,
Hilary Plant,
Chris Bailey,
Roger A'Hern
Abstract
Objective To evaluate the effectiveness of nursing intervention for breathlessness in patients with lung cancer.
Design Patients diagnosed with lung cancer participated in a multicentre randomised controlled trial where they either attended a nursing clinic o... (Read More)
ALFACELL Announces Phase II Malignant Mesothelioma Results
Business Wire - March 23, 1999
BLOOMFIELD, N.J.--(BUSINESS WIRE)--March 23, 1999--
Data on ONCONASE as a single agent presented in Italy
On Friday, March 19, 1999, ALFACELL Corporation (NASDAQ: ACEL) presented the results of its Phase II clinical trial testing its flagship product Onconase in patie... (Read More)
Pulmonary Cryptococcosis in Patients Without HIV Infection - )
Chest - March 1, 1999, by Judith A. Aberg,
Linda M. Mundy,
William G. Powderly
Purpose: To further elucidate the diagnostic and therapeutic approaches to patients with pulmonary cryptococcosis who are not HIV-infected.
Subjects: All of the patients without HIV infection who received care at two Midwest hospitals between January 1986 and February 1... (Read More)
Fine-Needle Interstitial Photodynamic Therapy of the Lung Parenchyma - )
Chest - February 1, 1999, by David I. Fielding,
Giovanni A. Buonaccorsi,
Alexander J. MacRobert,
Andrew M. Hanby,
Martin R. Hetzel,
Stephen G. Bown
Photosensitizer Distribution and Morphologic Effects of Treatment
Study objective: To look at the effect of interstitial photodynamic therapy (PDT) in normal lung parenchyma to assess its potential for treating localized, peripheral lung tumors.
Design: Studies were p... (Read More)
|
